Compare TCPC & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TCPC | RXST |
|---|---|---|
| Founded | 2006 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 280.2M | 232.2M |
| IPO Year | 2006 | 2021 |
| Metric | TCPC | RXST |
|---|---|---|
| Price | $3.25 | $6.02 |
| Analyst Decision | Sell | Hold |
| Analyst Count | 2 | 10 |
| Target Price | $3.50 | ★ $9.78 |
| AVG Volume (30 Days) | 654.0K | ★ 1.4M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 18.23% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $134,479,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.06 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.08 | $4.48 |
| 52 Week High | $7.41 | $13.22 |
| Indicator | TCPC | RXST |
|---|---|---|
| Relative Strength Index (RSI) | 45.39 | 61.37 |
| Support Level | $3.10 | $5.90 |
| Resistance Level | $3.54 | $6.53 |
| Average True Range (ATR) | 0.10 | 0.38 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 51.92 | 96.23 |
BlackRock TCP Capital Corp is an externally-managed specialty finance company focused on middle-market lending. Its investment objective is to achieve high total returns through current income and capital appreciation, with an emphasis on principal protection. It seeks to achieve its investment objective through investments in debt securities of middle-market companies. The group generates returns through a combination of the receipt of contractual interest payments on debt investments and origination and similar fees, and, to a lesser extent, equity appreciation through options, warrants, conversion rights, or direct equity investments.
RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.